Ethic Inc. Incyte Corp Transaction History

Ethic Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$52.16 - $64.19 $7,250 - $8,922	139 Added 1.72%	8,205 $515,000
Q3 2023 Nov 14, 2023	BUY	$57.77 - $65.93 $125,591 - $143,331	2,174 Added 36.9%	8,066 $465,000
Q2 2023 Aug 14, 2023	BUY	$60.95 - $75.51 $86,609 - $107,299	1,421 Added 31.78%	5,892 $366,000
Q1 2023 May 12, 2023	SELL	$70.23 - $86.01 $34,904 - $42,746	-497 Reduced 10.0%	4,471 $323,000
Q4 2022 Feb 14, 2023	BUY	$67.18 - $84.11 $333,750 - $417,858	4,968 New	4,968 $399,000
Q2 2022 Aug 10, 2022	SELL	$66.18 - $83.18 $167,567 - $210,611	-2,532 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$66.02 - $79.71 $167,162 - $201,825	2,532 New	2,532 $201,000
Q1 2021 May 13, 2021	SELL	$76.02 - $100.5 $290,928 - $384,613	-3,827 Closed	0 $0
Q4 2020 Feb 10, 2021	BUY	$80.74 - $97.7 $308,991 - $373,897	3,827 New	3,827 $333,000

644

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16.1B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Ethic Inc., based on Form 13F filings with the SEC.

Stay updated on Ethic Inc. with notifications on news.